Clinical evidence supports the therapeutic effects of selective MAO inhibitors, such as selegiline, which exert a therapeutic effect in a variety of neuropsychiatric diseases.49,50 These findings validate MAOB as a promising therapeutic target, consistent with our findings that MAOB-mediated astrocytic GABA synthesis contributes to PTSD pathophysiology. The gene discussed is MAOB; the disease is post-traumatic stress disorder.